Cempra conducted a randomized, double-blinded Phase 3 trial which evaluated the efficacy and safety of oral solithromycin (5 days) compared to the oral fluoroquinolone, moxifloxacin (7 days), for the treatment of adult patients with CABP. As pneumococcal vaccines are becoming widely used worldwide, including PCV13 (children) and PPSV23 (adults), this phase 3 trial presented a unique opportunity to further evaluate the overall prevalence of pneumococcal types causing CABP, the correlation between the pneumococcal type isolated from the nasopharynx and those strains isolated from blood or sputum and the use of pneumococcal density in nasopharyngeal specimens for detecting pneumococcal pneumonia.
• Baseline microbiological evaluation included cultures of blood and sputum, detection of S. pneumoniae and Legionella pneumophila antigen in urine, L. pneumophila and Mycoplasma pneumoniae serologies (4-fold diagnostic rise in titers), quantitative real-time (lytA) PCR and culture of nasopharyngeal swabs for S. pneumoniae, culture and PCR of oropharyngeal swabs for M. pneumoniae, and sputum multiplex PCR for lower respiratory pathogens (Unyvero TM by Curetis).
Diagnosis of pneumococcal pneumonia
o Definitive (D-Spn): UAT+, culture positive (blood or high quality sputum)
o Probable (P-Spn): Spn detected using molecular diagnostics (NP swab lytA qPCR, sputum multiplex PCR)
• Spn isolates were serotyped by Quellung reactions using antisera produced by the Staten Serum Institute (SSI). Quellung reactions identify 91 pneumococcal serotypes, including all vaccine types. Figure 3 : ROC curve analysis for lytA qPCR diagnostic accuracy of pneumococcal pneumonia using a threshold of 1x10 3 copies/ml.
• S. pneumoniae was the most prevalent bacterial pathogen isolated in the Phase 3 CABP trial. Whereas 35 different Spn serotypes were identified, vaccine escape types were found in >38% of patients with Spn CABP.
• We observed a very strong correlation (>89%) between the pneumococcal serotype isolated from blood or sputum, utilized as definitive diagnoses of pneumococcal pneumonia, and those isolated from the nasopharynx of Spn pneumonia patients.
• The use of qPCR of NP swabs significantly increased the rate of identification of Spn as the cause of CABP.
• Diagnosis by NP swab PCR was better correlated with blood culture (67%), sputum culture (55%) and UAT (46%), than any of these more traditional diagnostic methods were with one another.
• The most frequently identified CABP pathogens in order of prevalence: 14%   1  2  3  4  6A  6B  6C  7C  7F  8  9A  9N  9V  10A  11A  11B  13  14  15A  15C  16F  17A  17F  18B  18C  19A  19F  22F  23A  23F  33F  35B  35F  31 
Abstract
Background: Streptococcus pneumoniae (Spn) is the most common pathogen associated with communityacquired bacterial pneumonia (CABP). However, the detection of Spn in CABP patients can be challenging due to difficulties in quality sputum collection, low recovery of isolates from specimens that must be transported over distances to microbiology laboratories, and the low sensitivity of urinary antigen tests. In this global Phase 3 trial to evaluate the efficacy and safety of solithromycin compared to moxifloxacin in the treatment of CABP in adults, multiple microbiological and diagnostic methods were utilized to identify Spn.
Methods:
Patients had acute onset of radiologically confirmed CABP with consistent clinical signs and symptoms. Spn was identified as an etiologic agent on the basis of blood or sputum culture, urine antigen testing (UAT; BINAX), sputum multiplex PCR (Curetis) and quantitative Spn PCR of nasopharyngeal (NP) swabs. The NP swab PCR assay targeted the Spn-specific lytA gene and a threshold of 1000 CFU/mL (determined by receiver operating characteristic curve analysis) was used to differentiate between nasopharyngeal colonization and pneumococcal pneumonia.
Results: 860 subjects were enrolled from 16 countries; not all patients had specimens available for analysis. Spn was the most frequently identified pathogen in the trial (23%). Pneumococcal bacteremia was diagnosed in 15 patients and 28 patients were positive by UAT. Spn was cultured from sputum meeting diagnostic criteria in 55 patients. Pneumococcal pneumonia was identified by NP swab PCR in 133 (15.5%) patients. The overlap of NP swab PCR with more traditional diagnostic modalities is shown in Table 2 . NP swab PCR positivity overlapped with blood cultures (67%) and UATs (46%) more frequently than sputum culture did with either (33% and 18%, respectively).
Conclusions:
The use of quantitative PCR of NP swabs in this Phase 3 trial significantly increased the rate of identification of Spn as the cause of CABP. Diagnosis by NP swab PCR was better correlated with blood culture, sputum culture and UAT, than any of these more traditional diagnostic methods were with one another. 
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